SCHEMBL1769639

SCHEMBL1769639

C1CC2CCC1N2.O=c1ccc(-c2cccc(C(F)(F)F)c2)n[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.53
NTRK1 P04629 1/20 0.53
RET P07949 1/20 0.53
PDGFRB P09619 1/20 0.53
CDK8 P49336 1/20 0.53
NTRK3 Q16288 1/20 0.53
NTRK2 Q16620 1/20 0.53
AURKB Q96GD4 1/20 0.53
MEN1 O00255 1/20 0.52
POLB P06746 1/20 0.52
KMT2A Q03164 1/20 0.52
XDH P47989 1/20 0.47
CYP1A2 P05177 1/20 0.47
AKR1B1 P15121 2/20 0.46
NOTUM Q6P988 1/20 0.46
IDO1 P14902 1/20 0.46
MAP4K4 O95819 1/20 0.43
PIM1 P11309 1/20 0.43
GPX4 P36969 1/20 0.43
GSK3B P49841 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1769732 0.89 JAK2 (0.62) JAK2NTRK1RETPDGFRBCDK8
SCHEMBL10353459 0.74 CYP1A2 (0.74) JAK2NTRK1RETPDGFRBCDK8
SCHEMBL10966762 0.72 LMNA (0.61) JAK2NTRK1RETPDGFRBCDK8
SCHEMBL8897726 0.71 JAK2 (0.46) JAK2NTRK1RETPDGFRBCDK8
SCHEMBL11515630 0.70 IDO1 (0.60) MEN1POLBKMT2AXDHNOTUM
SCHEMBL11622724 0.70 NOTUM (0.55) JAK2NTRK1RETPDGFRBCDK8
SCHEMBL1301730 0.70 CYP1A2 (0.62) MEN1KMT2ACYP1A2NOTUMIDO1
Hydrochloric Acid SCHEMBL30367906 0.70 LMNA (0.59) JAK2NTRK1RETPDGFRBCDK8
SCHEMBL24155844 0.70 JAK2 (0.50) JAK2NTRK1RETPDGFRBCDK8
SCHEMBL30745160 0.69 XDH (0.59) JAK2NTRK1RETPDGFRBCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9212146-B2 Substituted pyridazinones for the treatment of tumors SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2015-12-15 US disclosed
US-20130281426-A1 PYRIDAZINONES, THE PREPARATION METHOD AND THE USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES 2013-10-24 US disclosed
US-8501731-B2 Derivatives of 6[3-(trifluoromethyl)phenyl]pyridazin-3(2H)-one having antitumor activity SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2013-08-06 US disclosed
EP-2253625-B1 PYRIDAZINONES, THE PREPARATION AND THE USE THEREOF SHANGHAI INST MATERIA MEDICA (CN) 2013-03-13 EP disclosed
US-20110112061-A1 PYRIDAZINONES, THE PREPARATION AND THE USE THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2011-05-12 US disclosed
EP-2253625-A1 PYRIDAZINONES, THE PREPARATION AND THE USE THEREOF Shanghai Institute Materia Medica, Chinese Academy Of Sciences (CN) 2010-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112061-A1 PYRIDAZINONES, THE PREPARATION AND THE USE THEREOF PDXK, PNPO, HCCS JAK2 1334/4885NTRK1 1863/4885RET 2636/4885
US-20130281426-A1 PYRIDAZINONES, THE PREPARATION METHOD AND THE USE THEREOF CYP3A5, PDXK, HCCS JAK2 1378/4885NTRK1 2186/4885RET 2797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.